GMAB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Genmab A/S (GMAB) is not a strong buy for a beginner long-term investor at this time. While the company has positive long-term catalysts in 2026 and beyond, the current technical indicators, financial performance, and lack of immediate trading signals suggest holding off on investment until clearer upward momentum or stronger signals emerge.
The MACD is positive and expanding, indicating mild bullish momentum. However, the RSI is neutral at 44.702, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 25.187, and resistance is at 26.631. The stock is trading near resistance but lacks strong upward momentum.
Analysts highlight 2026 as a 'catalyst-rich' year with key clinical readouts and potential sales growth. Wolfe Research and Wells Fargo see current levels as a 'buy the dip' opportunity. Recent acquisitions mitigate terminal value risk, and analysts are optimistic about the company's pipeline replenishing sales post-2029.
Financial performance in Q4 2025 showed a significant decline in net income (-94.38% YoY) and EPS (-94.26% YoY), raising concerns about profitability. No significant insider or hedge fund activity suggests a lack of strong institutional confidence.
In Q4 2025, revenue increased by 14.63% YoY to $1.058 billion, but net income dropped by 94.38% YoY to $31 million. EPS also fell by 94.26% YoY to 0.49, and gross margin declined slightly to 92.34%. While revenue growth is promising, profitability metrics are a concern.
Most analysts maintain a Buy rating, with price targets ranging from $32 to $48. Analysts are optimistic about the company's pipeline and upcoming catalysts in 2026, but near-term performance remains uncertain. Wolfe Research and Wells Fargo view the current price as an opportunity, while Guggenheim lowered its price target due to revised near-term estimates.
